Friday, November 17, 2017 11:05:06 AM
November 17, 2017 Hot Stocks Point Staff 0 Comment Inc, INO, Inovio Pharmaceuticals, NASDAQ: INO
US stocks rose and the dollar edged higher against a basket of major currencies on Thursday after the US House of Representatives passed its version of a tax overhaul bill.
Earnings-related gains in Wal-Mart and Cisco also boosted stocks, and the MSCI index of world stocks rose after 5 successive daily losses.
The Dow Jones Industrial Average and the S&P 500 chalked up their biggest percentage gains in over 2 months.
The House approved a broad package of tax cuts affecting businesses, individuals and families, moving Republicans and President Donald Trump an important step closer to the biggest tax code overhaul in a generation.
The legislative battle now shifts to the Senate, where the Republican majority is much slimmer. Republicans can lose no more than 2 Senate votes and at least 2 GOP senators have already spoken against the Senate version of the bill. (Source: ABS-CBN News)
The dollar index, which hit 93.813 on Wednesday, it’s lowest since Oct. 20, was also supported by a general improvement in risk appetite across financial markets. The index was last up 0.1 percent.
The Dow rose 187.08 points, or 0.8 percent, to 23,458.36, the S&P 500 gained 21.02 points, or 0.82 percent, to 2,585.64 and the Nasdaq Composite added 87.08 points, or 1.3 percent, to 6,793.29.
Major News: Amazon.com, Inc. (AMZN) stock inclined 0.94% to trade at $1137.29. Amazon.com (AMZN.O) will exclusively stream 37 top men’s tennis tournaments from 2019 to its Amazon Prime Video subscribers in Britain and Ireland after it won the ATP broadcast rights from pay-TV group Sky (SKYB.L).
The deal underlines Amazon’s ambition to challenge traditional pay-TV providers by using exclusive sports and entertainment content to attract people to its video service.
Amazon will also be the pay-TV partner for the season-ending Nitto ATP Finals at The O2 in London, and from 2018 the Queen’s Club Championships and the Eastbourne International, ATP said. (Source: Reuters)
A total volume of 2,196,237 shares was traded. The Company’s shares have inclined 14.07% in the past month, 52.35% in the last twelve months, and 51.66% on an YTD basis.
Stock to Watch: Inovio Pharmaceuticals, Inc. (NASDAQ: INO)
On Thursday, Shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) expressed a change of 3.57% and closed its trade at $4.64. The stock exchanged hands with 1,045,082 numbers of shares compared to its average daily volume of 1.21M shares. When trading is lighter than usual, it is said to be “thin.” When there’s more trading than usual, it is called “heavy trading.” Volume is the basic fuel of the market since stocks move up or down in price only when shares are trading hands.
The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $391.24M. The company has its outstanding shares of 84.32M. Outstanding shares refer to a company’s stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company’s officers and insiders. After a recent check, it is observed that the insiders for the firm currently own 3.60% shares. There has been an observed change of -0.26% in the ownership of the shares in the past six months. However, the institutional investors are observed to own 25.40% of the total shares. During last 3 month period, 0.52% of total institutional ownership has changed in the company shares.
What Historical Figures Say About Inovio Pharmaceuticals, Inc. (NASDAQ: INO)?
Before trading, trader, investor or shareholder must have an eye on stock’s historical performance. Analysts review historical return data when trying to predict future returns or to estimate how a security might react to a particular situation, such as a drop in consumer demand. Historical returns can also be useful when estimating where future points of data may fall in terms of standard deviations.
Analyzing historical data can give some perception of how a security or market has reacted to various different variables, from regular economic cycles to sudden world events. Shareholders looking to interpret historical returns should keep one caveat in mind: you can’t assume that the future will be like the past. The older the historical return data is, the more likely it is to be less useful when predicting future returns. Historical return data for INO stock is described below:
Looking into last 5 trades, the stock observed a return of almost 4.74%. However, -26.58% over the last one month, -14.86% for the last quarter and year to date performance stands at -33.14%.
Important Technical Indicators to Consider:
ATR value of the company was 0.26 and Relative Strength Index (RSI) was 33.85. The stock volatility for the week was 6.72% while for the month was 4.84%. The stock was trading at a distance of -52.94% from its 52-week highs and stands 10.48% away from its 52-week lows. INO’s latest closing price was -28.76% away from the average price of 200 days while it maintained a distance of -21.79% from the 50 Day Moving Average and -14.86% away compared to its SMA 20.
Analysts’ Suggestions in the Limelight:
Analysts have given a mean recommendation of 1.70 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range). The mean target price as estimated by the analysts for the company has been recorded at $11.83.
Disclaimer: Any news, report, research, and analysis published on Hotstockspoint.com are only for information purposes. Hot Stocks Point (HSP) makes sure to keep the information up to date and correct, but we didn’t suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own. Information in this release is fact checked and produced by competent editors of Hot Stocks Point; however, human error can exist.
__________________________________________________
http://www.hotstockspoint.com/2017/11/hot-stock-evaluation-inovio-pharmaceuticals-inc-nasdaq-ino/
I don't know the website but this article could be contributing to what has started as a good day.
INO
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM